Global expansion Volta Medical is expanding rapidly across Europe and the US, supported by multiple partnerships with leading centers. This signals growing demand and potential for regional sales teams to target major cardiology centers, hospitals, and electrophysiology laboratories that are already collaborating with Volta or in adjacent markets.

Next-gen adoption The launch of AF-Xplorer II and ongoing CE mark and FDA clearances indicate a pipeline of upgraded AI-enabled tools. Sales opportunities exist in upselling to existing customers and converting trial or pilot users of legacy AF-Xplorer to the newer AF-Xplorer II, as well as expanding use cases in complex atrial fibrillation and atrial tachycardia procedures.

Strategic partnerships Joint development agreements with GE Healthcare highlight a strong channel and tech alliance potential. There is room to explore co-selling, integration with imaging or mapping platforms, and broader collaboration with large OEMs or health tech providers to accelerate adoption in hospital networks and academic centers.

Regulatory momentum Having CE marking and FDA clearance establishes credibility and market access in key regions. Focus sales efforts on institutions requiring certified AI-assisted tools for complex ablations, leveraging regulatory wins to ease procurement and shorten cycle times for hospital adoption and capital expenditure approvals.

Award-backed credibility Prix Galien recognitions and industry accolades enhance credibility with procurement teams and clinicians. Use these awards in value propositions, case studies, and RFP responses to differentiate Volta’s AI-enabled electrophysiology solutions and justify total cost of ownership in competitive tenders.